BIOGEN INC (BIIB)

US09062X1037 - Common Stock

223.32  +0.84 (+0.38%)

After market: 223.82 +0.5 (+0.22%)

Fundamental Rating

5

BIIB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 599 industry peers in the Biotechnology industry. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BIIB has a valuation in line with the averages, but it does not seem to be growing.



8

1. Profitability

1.1 Basic Checks

BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
In the past 5 years BIIB has always been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of 4.33%, BIIB belongs to the best of the industry, outperforming 95.44% of the companies in the same industry.
With an excellent Return On Equity value of 7.85%, BIIB belongs to the best of the industry, outperforming 95.44% of the companies in the same industry.
With an excellent Return On Invested Capital value of 7.53%, BIIB belongs to the best of the industry, outperforming 95.95% of the companies in the same industry.
BIIB had an Average Return On Invested Capital over the past 3 years of 11.97%. This is in line with the industry average of 13.46%.
The 3 year average ROIC (11.97%) for BIIB is well above the current ROIC(7.53%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 4.33%
ROE 7.85%
ROIC 7.53%
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)11.97%
ROIC(5y)17.09%

1.3 Margins

The Profit Margin of BIIB (11.81%) is better than 96.28% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
The Operating Margin of BIIB (20.84%) is better than 96.96% of its industry peers.
BIIB's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 74.24%, BIIB belongs to the best of the industry, outperforming 84.80% of the companies in the same industry.
BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 20.84%
PM (TTM) 11.81%
GM 74.24%
OM growth 3Y-17.42%
OM growth 5Y-15.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.99%
GM growth 5Y-3.01%

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
BIIB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BIIB is higher compared to a year ago.

2.2 Solvency

BIIB has an Altman-Z score of 3.30. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.30, BIIB is doing good in the industry, outperforming 72.13% of the companies in the same industry.
BIIB has a debt to FCF ratio of 5.61. This is a neutral value as BIIB would need 5.61 years to pay back of all of its debts.
The Debt to FCF ratio of BIIB (5.61) is better than 94.76% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that BIIB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.46, BIIB is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 5.61
Altman-Z 3.3
ROIC/WACC0.71
WACC10.65%

2.3 Liquidity

BIIB has a Current Ratio of 2.00. This is a normal value and indicates that BIIB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.00, BIIB is doing worse than 79.39% of the companies in the same industry.
A Quick Ratio of 1.26 indicates that BIIB should not have too much problems paying its short term obligations.
BIIB has a Quick ratio of 1.26. This is amonst the worse of the industry: BIIB underperforms 86.15% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.26

3

3. Growth

3.1 Past

The earnings per share for BIIB have decreased strongly by -18.27% in the last year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.49% yearly.
Looking at the last year, BIIB shows a decrease in Revenue. The Revenue has decreased by -3.32% in the last year.
The Revenue has been decreasing by -6.07% on average over the past years.
EPS 1Y (TTM)-18.27%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS growth Q2Q-18.52%
Revenue 1Y (TTM)-3.32%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Revenue growth Q2Q-6.2%

3.2 Future

The Earnings Per Share is expected to grow by 9.22% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.13% on average over the next years.
EPS Next Y6.24%
EPS Next 2Y11.8%
EPS Next 3Y10.09%
EPS Next 5Y9.22%
Revenue Next Year-2.16%
Revenue Next 2Y0.26%
Revenue Next 3Y0.93%
Revenue Next 5Y2.13%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.81 indicates a correct valuation of BIIB.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.97% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.35, BIIB is valued a bit cheaper.
BIIB is valuated correctly with a Price/Forward Earnings ratio of 13.94.
97.64% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.63. BIIB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.81
Fwd PE 13.94

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 96.11% of the companies listed in the same industry.
BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIIB is cheaper than 96.45% of the companies in the same industry.
Industry RankSector Rank
P/FCF 26.18
EV/EBITDA 15.03

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIIB does not grow enough to justify the current Price/Earnings ratio.
BIIB has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.37
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3Y10.09%

0

5. Dividend

5.1 Amount

BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BIOGEN INC

NASDAQ:BIIB (2/23/2024, 7:00:01 PM)

After market: 223.82 +0.5 (+0.22%)

223.32

+0.84 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.36B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 14.81
Fwd PE 13.94
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.37
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.33%
ROE 7.85%
ROCE
ROIC
ROICexc
ROICexgc
OM 20.84%
PM (TTM) 11.81%
GM 74.24%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2
Quick Ratio 1.26
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-18.27%
EPS 3Y-22.83%
EPS 5Y
EPS growth Q2Q
EPS Next Y6.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.32%
Revenue growth 3Y-9.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y